The effect of sinomenine in diabetic neuropathic pain mediated by the P2X3 receptor in dorsal root ganglia

Rao, Shenqiang; Liu, Shuangmei; Zou, Lifang; Jia, Tianyu; Zhao, Shanhong; Wu, Bing; Yi, Zhihua; Wang, Shouyu; Xue, Yun; Gao, Yun; Xu, Changshui; Li, Guilin; Xu, Hong; Zhang, Chunping; Liang, Shangdong

doi:10.1007/s11302-016-9554-z

Cited by 42 publications

(32 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…P2X3R antagonists have been proposed for the treatment of diabetic neuropathic pain ( Guo et al, 2015 ; Zhang et al, 2015b ; Peng et al, 2017 ; Rao et al, 2017 ). Recently P2X7R have also been claimed to be involved in painful diabetic neuropathy in rats ( Liu et al, 2017 ).…”

Section: Endocrine Diseasesmentioning

confidence: 99%

Purinergic Signalling: Therapeutic Developments

2017

View full text Add to dashboard Cite

Purinergic signalling, i.e., the role of nucleotides as extracellular signalling molecules, was proposed in 1972. However, this concept was not well accepted until the early 1990’s when receptor subtypes for purines and pyrimidines were cloned and characterised, which includes four subtypes of the P1 (adenosine) receptor, seven subtypes of P2X ion channel receptors and 8 subtypes of the P2Y G protein-coupled receptor. Early studies were largely concerned with the physiology, pharmacology and biochemistry of purinergic signalling. More recently, the focus has been on the pathophysiology and therapeutic potential. There was early recognition of the use of P1 receptor agonists for the treatment of supraventricular tachycardia and A2A receptor antagonists are promising for the treatment of Parkinson’s disease. Clopidogrel, a P2Y12 antagonist, is widely used for the treatment of thrombosis and stroke, blocking P2Y12 receptor-mediated platelet aggregation. Diquafosol, a long acting P2Y2 receptor agonist, is being used for the treatment of dry eye. P2X3 receptor antagonists have been developed that are orally bioavailable and stable in vivo and are currently in clinical trials for the treatment of chronic cough, bladder incontinence, visceral pain and hypertension. Antagonists to P2X7 receptors are being investigated for the treatment of inflammatory disorders, including neurodegenerative diseases. Other investigations are in progress for the use of purinergic agents for the treatment of osteoporosis, myocardial infarction, irritable bowel syndrome, epilepsy, atherosclerosis, depression, autism, diabetes, and cancer.

show abstract

Section: Endocrine Diseasesmentioning

confidence: 99%

Purinergic Signalling: Therapeutic Developments

2017

View full text Add to dashboard Cite

show abstract

“…Sinomenine, an alkaloid derived from Sinomenium acutum , is a chief ingredient that has been reported to have a variety of pharmacological properties including anxiolytic effects ( Rao et al ., 2017 ). From a recent experiment, sinomenine enhanced pentobarbital-induced sleeping behaviors, and modulate sleep architecture via GABA A -ergic systems in rodents, ultimately increasing NREM sleep.…”

Section: Natural Products Which Have Proven To Be Effective For Sleepmentioning

confidence: 99%

Sleep-Aids Derived from Natural Products

et al. 2018

Biomolecules & Therapeutics

View full text Add to dashboard Cite

Although drugs such as barbiturates and benzodiazepines are often used for the treatment of insomnia, they are associated with various side effects such as habituations, tolerance and addiction. Alternatively, natural products with minimal unwanted effects have been preferred for the treatment of acute and/or mild insomnia, with additional benefits of overall health-promotion. Basic and clinical researches on the mechanisms of action of natural products have been carried out so far in insomnia treatments. Recent studies have been focusing on diverse chemical components available in natural products, with an interest of developing drugs that can improve sleep duration and quality. In the last 15 years, our co-workers have been actively looking for candidate substances from natural products that can relieve insomnia. This review is, therefore, intended to bring pharmacological data regarding to the effects of natural products on sleep duration and quality, mainly through the activation of GABAA receptors. It is imperative that phytochemicals will provide useful information during electroencephalography (EEG) analysis and serve as an alternative medications for insomnia patients who are reluctant to use conventional drugs.

show abstract

“…Many alkaloids such as SIN, disinoimenine, sinactine, sinoactine, acutumine, and magnoflorine, as well as the lignan syringaresinol have been isolated from Sinomenium acutum ( Bao et al ., 2005 ; Wang et al ., 2007 ; Jin et al ., 2008 ). Among them, SIN has been reported to have a variety of pharmacological effects including anti-rheumatism, immunomodulation and sedative effects ( Chen et al ., 1997 ; Li et al ., 2003 ; Rao et al ., 2017 ). Recently, it was reported that Sinomenium acutum , has sedative and anxiolytic effects mediated by GABA-ergic systems.…”

Section: Discussionmentioning

confidence: 99%

“…Sinomenine (SIN; Fig. 1 ), an alkaloid derived from Sinomenium acutum , is a chief ingredient which has been reported to have a variety of pharmacological effects including anti-rheumatism, immunomodulation and anxiolytic-like effects ( Chen et al ., 1997 ; Li et al ., 2003 ; Rao et al ., 2017 ). However, it has not been studied whether SIN is sedative or affects sleep behaviors.…”

Section: Introductionmentioning

confidence: 99%

Sinomenine, an Alkaloid Derived fromSinomenium acutumPotentiates Pentobarbital-Induced Sleep Behaviors and Non-Rapid Eye Movement (NREM) Sleep in Rodents

Yoo

Hong

et al. 2017

Biomolecules & Therapeutics

View full text Add to dashboard Cite

Sinomenium acutum has been long used in the preparations of traditional medicine in Japan, China and Korea for the treatment of various disorders including rheumatism, fever, pulmonary diseases and mood disorders. Recently, it was reported that Sinomenium acutum, has sedative and anxiolytic effects mediated by GABA-ergic systems. These experiments were performed to investigate whether sinomenine (SIN), an alkaloid derived from Sinomenium acutum enhances pentobarbital-induced sleep via γ-aminobutyric acid (GABA)-ergic systems, and modulates sleep architecture in mice. Oral administration of SIN (40 mg/kg) markedly reduced spontaneous locomotor activity, similar to diazepam (a benzodiazepine agonist) in mice. SIN shortened sleep latency, and increased total sleep time in a dose-dependent manner when co-administrated with pentobarbital (42 mg/kg, i.p.). SIN also increased the number of sleeping mice and total sleep time by concomitant administration with the sub-hypnotic dosage of pentobarbital (28 mg/kg, i.p.). SIN reduced the number of sleep-wake cycles, and increased total sleep time and non-rapid eye movement (NREM) sleep. In addition, SIN also increased chloride influx in the primary cultured hypothalamic neuronal cells. Furthermore, protein overexpression of glutamic acid decarboxylase (GAD65/67) and GABAA receptor subunits by western blot were found, being activated by SIN. In conclusion, SIN augments pentobarbital-induced sleeping behaviors through GABAA-ergic systems, and increased NREM sleep. It could be a candidate for the treatment of insomnia.

show abstract

The effect of sinomenine in diabetic neuropathic pain mediated by the P2X3 receptor in dorsal root ganglia

Cited by 42 publications

References 44 publications

Purinergic Signalling: Therapeutic Developments

Purinergic Signalling: Therapeutic Developments

Sleep-Aids Derived from Natural Products

Sinomenine, an Alkaloid Derived fromSinomenium acutumPotentiates Pentobarbital-Induced Sleep Behaviors and Non-Rapid Eye Movement (NREM) Sleep in Rodents

Contact Info

Product

Resources

About